GLG News by Mood Disorder Psychiatrists

Amit Vijapura, Owner

Amit VijapuraOwnerAMIT VIJAPURA MD What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Lilly has great product pipe line for Schizophrenia and other Psychiatric Disorders

September 24, 2007

Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds | www.pipelinereview.com

Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity for Lilly to continue with its leaders ship position in Psychiatry market, which is a fasted growing sector in medical research. LY2140023 is still going thru Phase II trials and its results are not yet released.

Amit Vijapura, Owner

Amit VijapuraOwnerAMIT VIJAPURA MD What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Quetiapine and Borderline personality disorder

September 1, 2006

Quetiapine Effective for Borderline Personality Disorder | www.medscape.com

How is Borderline personality disorder treated in Psychiatry practice ?
Use of Quetiapine (Seroquel) in B.P.D.

Amit Vijapura, Owner

Amit VijapuraOwnerAMIT VIJAPURA MD What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

ADHD treatment with Stimulant drugs and current FDA warning

August 24, 2006

UPDATE 2-US FDA calls for new warnings on ADHD drugs | yahoo.reuters.com

Treatment of ADHD is fastest growing market in USA and abroad. New warning by FDA can affect prescription growth and can have major impact on companies like SHIRE who is heavily relying on Stimulant medication use for their profit.

Page : 11 to 3 of 3

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News